問卷

TPIDB > Search Result > Clinical Trials List

Clinical Trials List

Protocol NumberGO44145
Active

2023-08-01 - 2032-06-30

Phase III

Recruiting7

ICD-10C83.30

Diffuse large B-cell lymphoma, unspecified site

ICD-10C83.39

Diffuse large B-cell lymphoma, extranodal and solid organ sites

ICD-10C84.60

Anaplastic large cell lymphoma, ALK-positive, unspecified site

ICD-10C84.69

Anaplastic large cell lymphoma, ALK-positive, extranodal and solid organ sites

ICD-10C84.70

Anaplastic large cell lymphoma, ALK-negative, unspecified site

ICD-10C84.79

Anaplastic large cell lymphoma, ALK-negative, extranodal and solid organ sites

ICD-10C85.20

Mediastinal (thymic) large B-cell lymphoma, unspecified site

ICD-10C85.21

Mediastinal (thymic) large B-cell lymphoma, lymph nodes of head, face, and neck

ICD-10C85.22

Mediastinal (thymic) large B-cell lymphoma, intrathoracic lymph nodes

ICD-10C85.23

Mediastinal (thymic) large B-cell lymphoma, intra-abdominal lymph nodes

ICD-10C85.24

Mediastinal (thymic) large B-cell lymphoma, lymph nodes of axilla and upper limb

ICD-10C85.25

Mediastinal (thymic) large B-cell lymphoma, lymph nodes of inguinal region and lower limb

ICD-10C85.26

Mediastinal (thymic) large B-cell lymphoma, intrapelvic lymph nodes

ICD-10C85.27

Mediastinal (thymic) large B-cell lymphoma, spleen

ICD-10C85.28

Mediastinal (thymic) large B-cell lymphoma, lymph nodes of multiple sites

ICD-10C85.29

Mediastinal (thymic) large B-cell lymphoma, extranodal and solid organ sites

ICD-10C96.4

Sarcoma of dendritic cells (accessory cells)

ICD-10C96.5

Multifocal and unisystemic Langerhans-cell histiocytosis

ICD-10Z51.12

Encounter for antineoplastic immunotherapy

ICD-9200.00

Reticulosarcoma, unspecified site, extranodal solid organ sites

  • Trial Applicant

  • Sponsor

  • Trial scale

    Multi-Regional Multi-Center

  • Update

    2026/02/01

Investigators and Locations

The Actual Total Number of Participants Enrolled

0 Recruiting

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator 王銘崇

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator 吳育穎

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator 蕭聖諺

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator 裴松南

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator 蕭聖諺

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Condition/Disease

Objectives

Test Drug

Active Ingredient

Dosage Form

Dosage

Endpoints

Inclution Criteria

The Estimated Number of Participants

  • Taiwan

    60 participants

  • Global

    1130 participants